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osting by EAbstract Purpose: To prospectively compare the mean ADC generated from DWI, the mean cho-
line + creatine/citrate ratio generated from 3D MRS and the combined mean ADC and mean cho-
line + creatine/citrate ratio in the detection of prostate cancer, and to correlate between the
choline + creatine/citrate ratio and the aggressiveness of malignancy determined by Gleason score,
with histopathological examination of the excised gland as the reference standard.
Patients and methods: Forty-six patients with biopsy-proved cancer underwent pre-operative MRI
at 1.5 T. Axial T1, axial, coronal and sagittalT2-weighted, diffusion-weighted and 3D MRS using a
point-resolved spectroscopic sequence (PRESS) were acquired. The mean ADC, mean cho-
line + creatine/citrate ratio and combined parameters for malignant lesions are correlated with
the pathological results. For each malignant lesion choline + creatine/citrate ratio was correlated
with the aggressiveness of malignancy determined by Gleason score. Receiver operating character-
istic (ROC) curves were used to determine sensitivity, and speciﬁcity of the studied parameters, and
Kappa measures of agreement were calculated for prostate cancer detection.
Results: The mean ADC for tumor tissue was 1.0 ± 0.22 · 103 mm2/s (mean ± SD), and was sig-
niﬁcantly lower than that for non-tumor tissue 1.44 ± 0.28 · 103 mm2/s (p< 0.001). For MRS
study the mean (choline + creatine)/citrate ratio in tumor tissue was 1.98 ± 1.0, and was signiﬁ-
cantly higher than that for non-tumor tissue, 0.72 ± 0.39 (p< 0.001). By combining both ADC
values and (choline + creatine)/citrate ratio for differentiating malignant from non-malignant4038955.
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430 G.K. Gouhar et al.tissues a receiver operating characteristic analysis (ROC) curve showed Area under curve
(AUC= 0.93) and was signiﬁcantly higher than either (choline + creatine)/citrate ratio alone
(AUC= 0.86) (p< 0.001) or ADC value alone (AUC= 0.89) (p< 0.001). There is an increasing
(choline + creatine)/citrate ratio with increasing Gleason score, however, there is overlap between
groups. A greater sensitivity of MRS for tumor detection 85% and 92% was present for tumors
with Gleason score 4 + 3 and P4 + 4, respectively, while for tumors with Gleason score 3 + 3
the sensitivity was 63%.
Conclusion: The combination of ADC and (choline + creatine)/citrate ratio is better than each
parameter alone in differentiating between tumor and non-tumor prostatic tissue, also MR spectro-
scopic imaging ﬁndings of prostate tumor (Cho + Cr)/Cit ratio correlate with pathologic Gleason
score. The combined parameters offer a promising non-invasive method for the diagnostic workup
of prostate cancer.
 2010 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Despite the recent development in the diagnosis and the treat-
ment of prostatic cancer, it continues to be the most common
cancer and the third leading cause of death in men (1). The
choice of treatment depends on a number of clinical parame-
ters and clinical nomograms such as the patient’s age at diag-
nosis, the stage and the aggressiveness of the tumor (2), with
the highest priority being the differentiation between indolent
and aggressive disease, which is based mainly on Gleason
grade determined by TRUS-guided biopsy (2). However, US
is of low accuracy in detection and localization of prostate can-
cer, so a random instead of targeted biopsy is performed.
Random sampling has several disadvantages such as miss-
ing of the cancer located outside the routine biopsy site and
unnecessary sampling of normal prostatic tissue. Moreover,
the site of previously negative biopsy cannot be determined
in patient with continuously high Prostatic Surface Antigen
(PSA) and the biopsy is repeated (3). Thus a non-invasive tech-
nique that allows accurate detection and assessment of the de-
gree of aggressiveness of prostatic cancer is needed to make a
substantial contribution to the decision-making process for
proper treatment selection (2).
The use of MRI as a non-invasive tool for the evaluation
and management of prostatic cancer has grown steadily in
the past decades (4). It allows functional assessment by differ-
ent techniques such as diffusion-weighted images (DWI) and
MR spectroscopy (MRS) (5). At 2WI prostate cancer appears
as a focus of low-signal intensity relative to bright normal
peripheral zone. However, prostate cancer is difﬁcult to detect
when it is in the central zone due to high-signal intensity from
benign prostatic hypertrophy (6). The accuracy of T2-weighted
MRI in tumor localization is 67–77% (7).
Diffusion-weighted MRI (DWI), a non-invasive technique
in which molecular motion of water is measured in biological
tissues, is now used in the detection of prostate cancer as an
adjunct to T2WI (8). The apparent diffusion coefﬁcient
(ADC) calculated from DWI in prostate cancer showed that
the mean ADC for malignant prostate is lower than the mean
ADC in the non-malignant prostatic tissue (9–11).
MR spectroscopic imaging has shown to provide an incre-
mental value to MRI regarding tumor detection and localiza-
tion (12), by providing information on relative concentration
of metabolites such as citrate (Cit), choline (Cho) and creatine
(Cr) within a voxel (13).In a previous study (14) a positive correlation between
ADC values, metabolites ratio (Cit to Cho and Cr) and PSA
was observed, and there was a direct relationship between
the reduction in (Cit) level and the malignant changes in pros-
tate (15).
Thus the purpose of this study is to evaluate the role of the
mean ADC with DWMRI and the mean metabolic ratio with
1H MR spectroscopic imaging in the detection of prostatic
cancer as well as the degree of aggressiveness of the lesion with
post-operative histopathological examination as the reference
standard.
2. Patients and methods
2.1. Patient characteristics
Forty-six men (mean age 61.5 ± 12.2 years) were included in
this prospective study who were scheduled for radical retropu-
bic prostatectomy or transurethral resection of the prostate
due to biopsy-proved cancer, within a mean 23 ± 19 days. A
minimum delay of 6 weeks was required between biopsy and
MR imaging and MR spectroscopic imaging to minimize
biopsy artifacts. Patient exclusion criteria were previous hor-
monal therapy, positive lymphadenectomy results, and contra-
indications to MR imaging (e.g., cardiac pacemakers,
intracranial clips). Informed consent was obtained from all
patients.
2.2. MR imaging protocol
MR imaging was performed with a 1.5-T Philips Achieva sys-
tem by using a pelvic phased-array coil with the patient in su-
pine position. MR imaging examination included
conventional, DW imaging and MR spectroscopy imaging.
2.2.1. Conventional images
After localizer images, conventional images were obtained
including transverse T1-weighted spin-echo MR images from
the aortic bifurcation to the symphysis pubis with the follow-
ing parameters: repetition time ms/echo time ms, 520/15 sec-
tion thickness, 4 mm; intersection gap, 1 mm; ﬁeld of view,
20 cm; matrix, 256 · 192 and ﬂip angle 90 deg. Thin-section
high-spatial-resolution transverse T2-weighted fast spin-echo
MR images of the prostate and seminal vesicles were obtained
with the following parameters: 3500/90, section thickness,
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256 · 192 and ﬂip angle 90 deg. Coronal and sagittal T2-
weighted fast spine echo MR images of the prostate and seminal
vesicles were obtained with the following parameters: 4100–
4500/90, section thickness, 3 mm; intersection gap, 1 mm; ﬁeld
of view, 38 cm; matrix, 256 · 192 and ﬂip angle 90 deg.
2.2.2. Diffusion-weighted imaging
Diffusion-weighted images were obtained by using single-shot
spin-echo echo-planar imaging with a pair of rectangular gra-
dient pulses along three orthogonal axes. The imaging param-
eters were as follows: 2800/74; ﬁeld of view, 38 cm2; section
thickness, 3 mm; intersection gap, 1 mm. Images were
zero-ﬁlled to a 256 · 256 matrix. The orientation and location
of these images were prescribed identically to the transverse
T2-weighted prostate images. The b values were 0 and
1000 s/mm2 and ﬂip angle 90 deg. Apparent diffusion coefﬁ-
cient (ADC) maps were automatically calculated by MRI ma-
chine software and included in the sequence for the
interpretation of DW imaging ﬁndings.
2.2.3. Three-dimensional 1H MR spectroscopy
2.2.3.1. Data acquisition. Three-dimensional (3D) MR spectro-
scopic imaging of the entire prostate was performed by using a
section-selected box drawn closely around the prostate and a
point-resolved spectroscopic sequence (PRESS). The 3D MR
spectroscopic imaging parameters were as follows: 1500/130;
number of signals acquired, one; spectral width, 1000 Hz;
number of points, 512; ﬁeld of view, 15 · 5.5 · 5.5 cm3. The
MR spectroscopic imaging acquisition voxel volume was
326.1 mm3. Magnetic ﬁeld homogeneity was optimized for
the selected volume by using an automated shimming algo-
rithm provided by the manufacturer.
2.2.3.2. Spectroscopic data analysis. Spectral data were pro-
cessed by using the manufacturer’s post-processing software
package. Processing included zero-ﬁlling of the raw data in
the superoinferior direction and reconstruction with a four-
dimensional Fourier transformation to yield 1H MR spectro-
scopic images. Estimates of the areas under the resonances
of the metabolite peaks were obtained by integrating a region
centered at each peak. The metabolites studied were those res-
onating at approximately 3.22 parts per million (ppm) (i.e.,
Cho), 3.02 ppm (i.e., Cr), and 2.62 ppm (i.e., Cit). The normal-
ized peak areas for Cho, Cr, and Cit for each tumor voxel were
tabulated and used to calculate the following ratios:
(Cho + Cr)/Cit, Cho/Cr, and Cho/Cit. In our study we used
the metabolic ratio maps of (choline + creatine)/citrate for
data management. For all voxels considered suspicious,
(Cho + Cr)/Cit was recorded for statistical analysis. The
MR spectroscopic imaging assignment of suspicious voxelsTable 1 Regression model for combining ADC and (choline + cre
B SE Wald
Step 1a ADC 6.075 1.336 20.684
MRS 1.864 0.554 11.312
Constant 6.154 1.782 11.923
a Variable(s) entered on step 1: ADC, MRS.was performed by using only (Cho + Cr)/Cit and without ref-
erence to the MR imaging ﬁndings or knowledge of the results
of pathologic evaluation.
2.3. Pathologic evaluation
Prostatectomy specimen was prepared and ﬁxed in 10% for-
malin. After parafﬁn embedding, microslices were placed on
glass slides and stained with hematoxylin and eosin. At patho-
logic analysis, grading was assigned to the lesion in the speci-
men according to the Gleason score.
2.4. Data and statistical analysis
Statistical analysis was performed by using statistical software
SPSS version 10. (Cho + Cr)/Cit value for each suspicious
voxel within the lesion was tabulated. The mean values of
(Cho + Cr)/Cit for each lesion and the total number of suspi-
cious voxels in the lesion were recorded for statistical analysis.
We used the mean ADC and the mean (choline + creatine)/
citrate ratio for each multivoxel ROI. The mean values of
the benign ROIs were compared with the mean values of the
malignant ROIs by using paired t tests.
Diffusion-weighted information and 3D MR spectroscopic
imaging information were combined by using generalized esti-
mating equations with an independent working correlation
matrix to account for the correlated data. To obtain predicted
probabilities of an ROI being cancerous, the mean ADC and
the mean (choline + creatine)/citrate ratio for the ROI were
entered into a logistic regression model. On the basis of the re-
sults of this model (Table 1), the following equation was ob-
tained for the probability of an ROI being cancerous:
6:15þADC  6:07MRS  1:864
The regression model yielded estimated regression coefﬁ-
cients that weighted the information from these two variables
in an optimal way for combining them. The regression analysis
also determined whether each variable was signiﬁcantly associ-
ated with the probability of an ROI being cancerous, after
adjusting for the other information. Receiver operating char-
acteristic curves and the corresponding areas under the recei-
ver operating characteristic curves (AUCs) were estimated
non-parametrically for the detection of cancer by using mean
ADC, mean (choline + creatine)/citrate ratio, and combined
mean ADC and mean (choline + creatine)/citrate values for
each ROI. In all statistical methods, a p value of less than
0.05 was considered to indicate a signiﬁcant difference. Be-
cause smaller ADC values are associated with cancer, for the
receiver operating characteristic analysis we transformed the
ADC value by multiplying it by 1. The sensitivity and spec-
iﬁcity of mean ADC, mean (choline + creatine)/citrate ratio,atine)/citrate ratio.
df Sig. Exp(B) 95.0% CI for exp(B)
Lower Upper
1 0.000 435.001 31.727 5964.106
1 0.001 0.155 0.052 0.459
1 0.001 0.002
Table 2 Mean ADC values (mean ± SD) and mean (cho-
line + creatine)/citrate ratio in malignant and benign tissues.
Parameters Mean t test
ADC (·103 mm2/s)
Malignant 1.0 ± 0.22 10.1
Benign 1.44 ± 0.28
(Choline + creatine)/citrate ratio
Malignant 1.98 ± 1.0 6.9
Benign 0.72 ± 0.39
Fig. 2 ROC curve shows mean ADC alone (green line)
(AUC= 0.89), (choline + creatine)/citrate ratio alone (red line)
(AUC= 0.86), and both ADC and (choline + creatine)/citrate
ratio (blue line) (AUC = 0.93).
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rate were measured and Kappa measures of agreement were
calculated.
MR spectroscopic imaging sensitivity for cancer detection
was analyzed prospectively by comparing the MR spectro-
scopic imaging voxels, which had been designated as suspi-
cious for cancer, with the pathologic ﬁndings. Sensitivity
was calculated for all pathologic lesions as a group and for
individual Gleason score groups (3 + 3, 3 + 4, 4 + 3, and
P4 + 4). Then MR spectroscopic imaging analysis tested
the hypothesis that MR spectroscopic imaging metabolite ra-
tios in true-positive lesions were related to pathologic Glea-
son scores. The relationship of Gleason scores for the
individual lesions to the MR spectroscopic imaging
(Cho + Cr)/Cit value was assessed. In each lesion, the MR
spectroscopic imaging mean ratio was compared with the
Gleason score for that lesion.
3. Results
A total of 46 patients underwent conventional MRI, DWI, and
MRS for prostatectomy. Twelve patients had a single lesion,
nineteen patients had two lesions, nine patients had tree lesions
and seven patients had four lesions.
There was an overlap between tumor and non-tumor mean
ADC values and the mean (choline + creatine)/citrate ratio
(Fig. 1A and B).
The mean ADC for tumor tissue was 1.0 ± 0.22 · 103
mm2/s (mean ± SD), and was signiﬁcantly lower than that
for non-tumor tissue 1.44 ± 0.28 · 103 mm2/s (p< 0.001)
(Table 2).
All prostatic cancer displayed high-signal intensity on DWI
and low-signal intensity on ADC map.
For MRS study the mean (choline + creatine)/citrate ratio
in tumor tissue was 1.98 ± 1.0, and was signiﬁcantly higher
than that for non-tumor tissue 0.72 ± 0.39 (p< 0.001) (Table
2).
By combining both ADC values and (choline + creatine)/
citrate ratio for differentiating malignant from non-malignant
tissues a receiver operating characteristic analysis (ROC) curve
showed Area under curve (AUC) = 0.93, 95% CI: 0.88–0.47
and was signiﬁcantly higher than either (choline + creatine)/
citrate ratio alone where AUC= 0.86, 95% CI: 0.80–0.92
(p< 0.001) or ADC value alone where AUC= 0.89, 95%
CI: 0.83–0.95 (p< 0.001). The latter was more accurate thanFig. 1 Box plot: (A) the mean ADC, (B) the mean (choline(choline + creatine)/citrate ratio alone, although the differ-
ence was not signiﬁcant (p> 0.05) (Fig. 2).
Of 151 lesions that were present in 46 patients included in
this study and were identiﬁed with pathologic examination,
105 lesions were detected by MRS. Of these 105 lesions de-
tected by MRS, 56 lesions had a Gleason score 3 + 3, 26 le-
sions had a Gleason score of 3 + 4, 11 lesions had a
Gleason score 4 + 3 and 12 lesions had a Gleason score
P4 + 4 Table 3.
Table 4 shows the sensitivity of MRS for tumor detection as
graded by Gleason score. A greater sensitivity 85% and 92%
was present for tumors with Gleason score 4 + 3 and+ creatine)/citrate ratio in malignant and benign tissues.
Table 4 Sensitivity of (choline + creatine)/citrate ratio for
detection of pathologically proved tumor as graded by Gleason
score.
(Cho + Cr)/Cit ratio Gleason score
3 + 3 3 + 4 4 + 3 P4 + 4 Total
True positive 56 26 11 12 105
False negative 33 10 2 1 46
Total 89 36 13 13 151
Sensitivity (%) 63 72 85 92 70
Fig. 3 Error bar shows mean (choline + creatine)/citrate ratio
versus Gleason score. *NB: there is an increasing (choline +
creatine)/citrate ratio with increasing Gleason score.
Table 5 Signiﬁcance (P value) of mean (choline + creatine)/
citrate ratio in differentiating the degree of aggressiveness of
tumor as regarded by Gleason score.
Gleason score 3 + 3 3 + 4 4 + 3 P4 + 4
3 + 3 NA 0.28 <0.001 <0.001
3 + 4 0.28 NA <0.005 <0.006
4 + 3 <0.001 <0.005 NA 0.12
P4 + 4 <0.001 <0.006 0.12 NA
Table 3 Area under curve (AUC), sensitivity and speciﬁcity of studied parameters.
Parameters AUC Sensitivity
(%)
Speciﬁcity
(%)
Positive predictive
value (PPV)
Negative predictive
value (NPP)
Kappa
test
ADC 0.89 81 84 92.4 66.1 0.60
(Cho + Cr)/Cit ratio 0.86 71.4 78.3 88.2 54.5 0.44
Combined ADC and
(Cho + Cr)/Cit ratio
0.93 94.2 85 93 86 0.80
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3 + 3 the sensitivity was 63%. This is explained by the fact
that the value of mean (choline + creatine)/citrate ratio in-
creased by an increase in Gleason score due to markedly ele-
vated choline levels associated with marked reduction in
citrate levels (high-grade tumors). On the other hand lesions
with low Gleason score had low mean (choline + creatine)/cit-
rate ratio due to slight elevation in choline levels associated
with slight reduction in citrate levels (low-grade tumors)
(Fig. 3).
For the discrimination between Gleason score in tumors
according to mean (choline + creatine)/citrate ratio there
was a signiﬁcant difference in lesions with low Gleason score
(3 + 3) versus lesions with higher Gleason score (4 + 3 or
P4 + 4) (p< 0.001), while lesions with Gleason score
(4 + 3) did not differ signiﬁcantly from those with Gleasonscore P4 + 4 (p> 0.05) (Table 5). Representative cases are
shown in Figs. 4–8.
4. Discussion
Recent advances offer newly developed sequences for MR
imaging. DWI has recently received attention as a promising
method in the diagnosis of prostate cancer. Currently, it is
the only technique that depicts differences in molecular diffu-
sion. Restricted diffusion in tumor tissue is attributed to histo-
pathological characteristics, such as greater cellular density
caused by a high index of neoplastic replication, enlargement
of nuclei and hyperchromatosis (16–19). The changes in diffu-
sion properties are calculated by the apparent diffusion coefﬁ-
cient (ADC) which is affected by both the Brownian motion of
water molecules and polluting factors from T2 tissue signals
(20). So cellular changes that inhibit the movement of water
molecules result in restricted diffusion and decreased ADC val-
ues in tumor tissues (21).
Several studies (22–24) have reported the high performance
of DWI in detecting prostate cancer.
In agreement with previous studies (9,25–30) this study
showed that the ADC value for malignant tissue was signiﬁ-
cantly lower (p< 0.001) than that for non-malignant tissue.
It was 1.0 ± 0.22 for tumor tissue and 1.44 ± 0.28 for non-tu-
mor tissue. The sensitivity speciﬁcity for detecting prostate
cancer were 81% and 84%, respectively.However, other stud-
ies (15,25,31) showed that the mean ADC values fall within a
wide range of values for tumor and non-tumor tissue. They ex-
plained the wide variation in ADC values by physiologic fac-
tors such as age, tumor size and grade and by technical
factors such as variations in acquisition parameters and post-
processing techniques.
MRS provides an idea about the relative concentration of
chemical metabolites in the prostatic tissue by using a small
values of interest (voxels) (1,2).
3D MRS detects the level of metabolites such as citrate,
choline and creatine, and making it possible to differentiate
tumor from non-tumor tissue. In prostate cancer the reduced
Fig. 4 Prostate cancer with Gleason score 4 + 4: axial T2WI (a) shows the cancer as an ill-deﬁned hypointense focal lesion at central
prostatic zone mainly to the left side. The tumor is hyperintense at DWI (b) and is of low-signal intensity at ADC map (c). 3D MRS at the
same level (d), 3D MRS of a voxel at the cancer site (e) shows elevated Cho + Cr/Cit ratio and 3D MRS of a voxel at a normal site (f)
shows normal Cho + Cr/Cit ratio.
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Fig. 5 Prostate cancer with Gleason score 3 + 4: axial T2WI (a) shows the cancer as a small well-deﬁned hypointense focal lesion at the
left prostatic lobe. The tumor is hyperintense at DWI (b) and is of low-signal intensity at ADC map (c). 3D MRS of the same section (d),
3D MRS of a cancerous voxel (e) shows elevated Cho + Cr/Cit ratio and 3D MRS of a normal voxel (f) shows normal Cho + Cr/Cit
ratio. A photomicrograph (g) shows Gleason score 3 + 4.
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Fig. 6 Prostate cancer with Gleason score 4 + 5: axial (a) and sagittal (d) T2WI show multiple cancerous well-deﬁned hypointense focal
lesions. The lesions are of high-signal intensity at DWI (b) and of low-signal intensity at ADC map (c). 3D MRS of the same section (e)
and 3D MRS of a cancerous voxel (f) shows elevated Cho + Cr/Cit ratio. A photomicrograph (g) shows Gleason score 4 + 5.
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rate-oxidizing metabolism, also the elevated choline level is due
to increased cell growth and proliferation of tumor cells as its
related phospholipid cell membrane turnover (1,2).
The choline and creatine are used in the spectral analysis in
3D MRS because both peaks are close to each other in the
spectral trace and even may be inseparable (2).
In this study we used 3D MRS to evaluate prostatic tissue.
By applying (Cho + Cr)/Cit ratio, this study showed that it
was possible to differentiate tumor tissue by high
(Cho + Cr)/Cit ratio (1.98 ± 1.0) for non-tumor tissue with
signiﬁcantly lower ratio (0.72 ± 0.39) (p< 0.001). The sensi-
tivity and speciﬁcity for 3D MRS in this study were 71.4%
and 78.3%, respectively. These ﬁndings agreed with the previ-
ous studies (7,32–37) regarding the ability of MRS to differen-
tiate tumor from non-tumor tissue.The strategy of cancer care in the new millennium is direc-
ted toward maximizing cancer control while minimizing the
risk of complication. The treatment of prostate cancer varied
from deferred therapy (watchful waiting), hormonal ablation,
radical surgery and different types of radiation therapy (38).
The variability in biological aggressiveness, and the biopsy
specimen are not accurate predictor of Gleason score and
are the most challenging characteristics of prostate cancer (2).
Regarding the degree of aggressiveness of prostate cancer,
this study showed that there was a trend toward an increasing
(Cho + Cr)/Cit ratio in association with higher Gleason score:
MRS showed higher sensitivity in detecting tumors of higher
degree of aggressiveness and was 92% in Gleason score
P4 + 4, and 85% in Gleason score 4 + 3; however, the sensi-
tivity was 63% for Gleason score 3 + 3. There were a signiﬁ-
cant difference (p< 0.001) in discriminating between lesions
Fig. 7 Prostate cancer with Gleason score 4 + 3: axial T2WI (a) shows the cancer as an ill-deﬁned hypointense focal lesion at the right
prostatic lobe. The tumor is hyperintense at DWI (b) and is of low-signal intensity at ADC map (c). MRS of the cancerous voxel (d) shows
elevated Cho + Cr/Cit ratio. Photomicrographs (e and f) show Gleason score 4 + 3.
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score (4 + 3 or P4 + 4). These ﬁndings agreed with the pre-
vious studies (39,40) regarding the correlation between MRS
(metabolite ratio) and tumor grade.
Previous studies (7,14,28) suggested that the combination
of both ADC and MRS has improved the diagnostic accuracy.
In consistence with these ﬁndings, our study showed that the
combination of both ADC and MRS had a higher sensitivity
94.2% and speciﬁcity 85% than each parameter alone. The
AUC in the combined parameters was 0.93 (Kappatest = 0.80) which is signiﬁcantly higher (p< 0.001) than
ADC alone where AUC= 0.89 and Kappa test 0.60 or
(Cho + Cr)/Cit ratio alone (AUC= 0.86 and Kappa
test = 0.44), However, Mazaheri et al. (15) stated that com-
bined DWI and MRS was not signiﬁcantly more accurate than
DWI alone.
In conclusion, the diagnostic power of combined DWI and
MRS in discrimination between tumor and non-tumor tissue
in prostate cancer is higher than a single parameter. The ability
of MRS to predict and discriminate between different degrees
Fig. 8 Prostate cancer with Gleason score 4 + 3: axial T2WI (a) shows the cancer as an ill-deﬁned iso- to hypointense focal lesion at
central prostatic zone. The tumor is hyperintense at DWI (b) and is of low-signal intensity at ADC map (c). 3D MRS at the same level (d),
3D MRS of a voxel at the cancer site (e) shows elevated Cho + Cr/Cit ratio, and 3D MRS of a voxel at a normal site (f) shows normal
Cho + Cr/Cit ratio.
438 G.K. Gouhar et al.of aggressiveness of prostate cancer as graded by Gleason
score would warrant the use of MRS in conjugation withDWI as a promising non-invasive parameters for the diagnos-
tic workup of prostate cancer.
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